Aug 2026· Health Science Reports· Vol 9· 0 citations· 129 references
Medicine
TL;DR
Metabolomics is unlikely to replace existing diagnostic modalities in the near future but may substantially improve diagnostic accuracy when integrated with established biomarkers, imaging techniques, and molecular diagnostics.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide because most patients are diagnosed at advanced stages when curative treatment is no longer feasible. Metabolomics has emerged as a promising strategy for identifying biochemical alterations associated with early tumor development and may improve the early detection of PDAC. This review critically evaluates the role of metabolomics in PDAC diagnosis, focusing on metabolite biomarkers, nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry‐based platforms, and machine learning assisted approaches.
Current evidence indicates that alterations in gut, oral and tumor-associated microbiota are associated with PDAC development and progression, supporting the potential diagnostic value of microbiome-based biomarkers in this disease.
Salivary metabolomics has emerged as a promising noninvasive approach for the early detection of oral squamous cell carcinoma (OSCC), enabling the identification of tumor-associated metabolic alterations with potential diagnostic value. Recent systematic reviews and meta-analyses have demonstrated encouraging diagnos...
Raghuram Manickam, V. Subramani· Journal of Primary Care Dent...· 0 citations
A large-scale metabolome relative quantitative method workflow using ultrahigh-performance liquid chromatography coupled with Q-TRAP mass spectrometry to identify novel biomarkers in the serum of CC patients demonstrates applicability in identifying potential metabolite biomarkers for CC and provides a promising tool f...
Shu-Ting Yu, Gui-Fang Ye, Jia-Xin Gai et al.· Journal of Proteome Research· 0 citations
This study demonstrates a clear link between altered lipid metabolism and cervical cancer, paving the way for future research to identify new diagnostic and prognostic markers and ultimately enabling earlier detection and timely intervention.
Akshata Kishore Karekar, Sandhya Kamat, Padmaja Y. Samant et al.· The Indian journal of medica...· 0 citations
It is argued that clinically useful signatures should be question-specific, stage-aware, and specimen-aware rather than universal multi-analyte panels and the need for prospective validation across clinically diverse populations is argued.
Ke Xu, Yu Liu, Yuan Peng et al.· Biofactors· 0 citations
The principles and major formats of protein microarray technologies and their applications in gastric cancer are summarized and current challenges and future directions for clinical translation are discussed.
Pan-Ning Wang, Yu-Lin Xiao, Shu-Hong Luo et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
